Lifeward Ltd SEC Filings

Lifeward Ltd. insider sale to cover taxes following RSU vesting. Jeannine Lynch, VP of Market Access & Strategy and a director, reported the sale of 1,591 ordinary shares on 09/02/2025 at $0.64 per share to satisfy tax withholding tied to RSUs that vested on 08/31/2025. After the sale she beneficially owns 46,067 ordinary shares indirectly, and the transaction was executed under an automatic sell-to-cover arrangement mandated by her RSU grant agreement. The filing states the sale was not a discretionary trade by the reporting person.

The filing amends prior Form S-8 registration statements to reflect Lifeward Ltd.'s replacement of its ReWalk Robotics Ltd. 2014 Incentive Compensation Plan with the Lifeward Ltd. 2025 Incentive Compensation Plan. Shareholders approved the 2025 Plan effective August 1, 2025. There are 164,129 ordinary shares underlying outstanding awards under the 2014 Plan that may become issuable under the 2025 Plan. No additional shares are being registered by this amendment.

Lifeward Ltd. (LFWD) filed a post-effective amendment to prior Form S-8 registration statements to reflect the shareholder-approved Lifeward Ltd. 2025 Incentive Compensation Plan (the "2025 Plan") effective August 1, 2025. The amendment covers 164,129 Ordinary Shares underlying awards outstanding under the Registrant's 2014 Plan that, following the Effective Date, may become issuable under the 2025 Plan. No additional securities are being registered. The filing notes prior registrations totaling 916,676 Ordinary Shares (post reverse-splits) and describes that forfeited or cancelled shares under the 2014 Plan will be added back to the 2025 Plan. The document also incorporates the Company’s recent SEC reports by reference and includes standard indemnification and insurance disclosures under Israeli law.

Lifeward Ltd. filed a Post-Effective Amendment to prior Form S-8 registration statements to reflect shareholder approval of the Lifeward Ltd. 2025 Incentive Compensation Plan effective August 1, 2025. The amendment covers 164,129 Ordinary Shares underlying awards outstanding under the prior 2014 Plan that may become issuable under the 2025 Plan. No new shares are being registered. The filing notes prior registrations and two reverse share splits (1-for-25 and 1-for-7) and incorporates specified reports and plan exhibits by reference.

Lifeward Ltd. shareholders approved the Lifeward Ltd. 2025 Incentive Compensation Plan on August 1, 2025. Following the Effective Date, no new awards will be granted under the ReWalk Robotics Ltd. 2014 Incentive Compensation Plan (the 2014 Plan) and 164,129 Ordinary Shares underlying existing awards under the 2014 Plan as of the Effective Date may be reallocated to the 2025 Plan if they become available. The filing amends prior S-8 registration statements to cover those 164,129 Outstanding Shares and notes prior registrations aggregated 916,676 Ordinary Shares (post reverse splits).

Lifeward Ltd. filed a Post-Effective Amendment on Form S-8 to transfer outstanding awards from its prior ReWalk Robotics Ltd. 2014 Incentive Compensation Plan into the Lifeward Ltd. 2025 Incentive Compensation Plan following shareholder approval on August 1, 2025. There are 164,129 ordinary shares underlying outstanding awards as of the Effective Date that will be covered to the extent they become issuable under the 2025 Plan. No additional securities are being registered. The filing notes prior reverse stock splits and incorporates by reference the company’s recent reports and governing documents.

Lifeward Ltd. filed a Form S-8 to register securities under its 2025 Incentive Compensation Plan for issuance to employees, executives and directors. The filing incorporates by reference the company’s recent annual and quarterly reports and numerous current reports, and lists exhibits including plan documents, award agreement forms for Israeli and non-Israeli participants, legal opinions, consents and a directors’ and officers’ insurance disclosure. The company describes indemnification, exculpation and insurance arrangements for office holders under Israeli law and confirms it has obtained D&O insurance and indemnification agreements to the fullest extent permitted. The filing is procedural and registers equity awards under the Plan.

Lifeward Ltd. reported lower revenues and widening losses in the quarter ended June 30, 2025. Quarterly revenue was $5.7 million versus $6.7 million a year earlier, and six‑month revenue totaled $10.8 million versus $12.0 million. The company recorded a quarterly operating loss of $6.6 million and a six‑month net loss of $11.4 million. Cash and cash equivalents were $5.1 million at June 30, 2025 and total cash, cash equivalents and restricted cash were $5.5 million, with management estimating runway into the fourth quarter of 2025, raising substantial doubt about going concern.

The company recorded a $2.8 million goodwill impairment in Q2 2025 and eliminated an earnout liability. Lifeward completed multiple 2025 equity financings, including a January registered direct offering and a June public offering (4.0 million shares with warrants), and raised proceeds under an ATM program (964,118 shares sold for net proceeds of about $1.0 million). A favorable Administrative Law Judge ruling and CMS actions have established a Medicare pathway for ReWalk (HCPCS code K1007) with a lump‑sum purchase payment of $91,032, a material reimbursement development for the ReWalk product line.

Lifeward Ltd. furnished a press release announcing its financial results for the second quarter ended June 30, 2025. The company will host a conference call to discuss those results at 8:30 a.m. E.D.T. on August 14, 2025, and an archived webcast will be available at the provided link and on the company’s Investors page for 30 days. The press release is furnished as Exhibit 99.1 and the cover page interactive XBRL is provided as Exhibit 104. The filing states these materials are furnished and are not to be deemed “filed” or incorporated by reference into other securities filings. The company’s ordinary shares trade under the LFWD ticker on the Nasdaq Capital Market.